Omeros Corporation (OMER)
-NasdaqGM | Prev Close: | 5.34 |
|---|
| Open: | N/A |
|---|
| Bid: | 4.59 x 200 |
|---|
| Ask: | 5.45 x 200 |
|---|
| 1y Target Est: | 15.63 |
|---|
| Beta: | 0.33 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.65 - 13.45 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 241,785 |
|---|
| Market Cap: | 138.46M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.60 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- OMEROS CORP FinancialsEDGAR Online Financials(Fri, May 17)
- Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common StockPR Newswire(Tue, May 14)
- Investors are Digesting These Healthcare Stock Earnings Insightsat Wall St. Cheat Sheet(Sun, May 12)
- Short Interest Jumps 41.2% For OMERat TheStreet(Fri, May 10)
- OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and ExEDGAR Online(Fri, May 10)
- Omeros Corporation Reports First Quarter 2013 Financial ResultsPR Newswire(Fri, May 10)
- Omeros Announces $16.2 Million Registered Direct Offering of Common StockPR Newswire(Thu, May 9)
- Omeros Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Thu, May 9)
- OMEROS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Omeros requests fast track designation for OMS824theflyonthewall.com(Wed, May 1)
- Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's DiseasePR Newswire(Wed, May 1)
- Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized ReviewPR Newswire(Tue, Apr 30)
- Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and CongressPR Newswire(Thu, Apr 25)
- Omeros to Present at the 12th Annual Needham Healthcare ConferencePR Newswire(Wed, Apr 24)
- Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and CongressPR Newswire(Fri, Apr 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 24.63 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.50 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.39 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.04 |
|---|
Business Summary
Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system.
View More 
0.12%